Home › Funds › Pavaki Capital Management LLC › SPRY
Pavaki Capital Management LLC position in SPRY
ARS PHARMACEUTICALS INC · Health Care
Pavaki Capital Management LLC reported holding 659,600 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$2.8M, representing 1.19% of its reported portfolio and ranking #19 among its reported holdings. Pavaki Capital Management LLC has disclosed SPRY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-10-26 · Source: SEC EDGAR Form 13F-HR
How Pavaki Capital Management LLC's SPRY position evolved
Pavaki Capital Management LLC first disclosed a stake in SPRY in Q4 2025 at 1,500 shares (US$17K). The position peaked in Q2 2026 at 579,600 shares, worth US$4.6M. Across 4 filings, Pavaki Capital Management LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 659,600 shares valued at US$2.8M — an increase of 80,000 shares quarter over quarter.. Notable position changes include a 38313% increase in Q1 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.50K | $17.48K | New |
| Q1 2026 | 576.20K | $4.63M | Add |
| Q2 2026 | 579.60K | $4.64M | Add |
| Q3 2026 | 659.60K | $2.84M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 25 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), ORBIMED ADVISORS LLC (US$66.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- ORBIMED ADVISORS LLC 8.29M sh · $66.39M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $60.11M · Q2 2026
- Tyro Capital Management LLC 4.46M sh · $35.72M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $32.14M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M sh · $9.08M · Q2 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K sh · $4.86M · Q2 2026
More on Pavaki Capital Management LLC
FAQ
How long has Pavaki Capital Management LLC held SPRY?
Pavaki Capital Management LLC has disclosed SPRY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Pavaki Capital Management LLC's current position in SPRY?
As of Q3 2026, Pavaki Capital Management LLC holds 659.60K shares of SPRY (ARS PHARMACEUTICALS INC), valued at $2.84M, representing 1.19% of its reported portfolio and ranking #19.
Has Pavaki Capital Management LLC been buying or selling SPRY?
In the latest 13F filing (Q3 2026), Pavaki Capital Management LLC increased its position in SPRY. The position peaked in Q2 2026 at 579.60K shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.